We just got accepted a paper where we have developed a new liposomal formulation against acute myeloid leukaemia. The liposomes carry daunorubicin and emetine for enhanced cytotoxic effect, and are coated with polyetylene-glycol to avoid being recognised by macrophages. They have also folate on their outside, which binds to folate receptor on the leukaemia cells. We also managed to increase cellular drug loading by enhancing folate receptor expression. This was done by anti-folate therapy (methotrexate). The paper is published in European Journal of Pharmaceutics and Biopharmaceutics.